Revisión web de drug-dev.com
Drug Development & Delivery - The Latest Methods in Drug Development
Generado el 15 Marzo 2026 09:34 AM
Resultados antiguos? ACTUALIZAR !
La puntuación es 64/100
Contenido SEO
Título
Drug Development & Delivery - The Latest Methods in Drug Development
Longitud : 68
Perfecto, tu título contiene entre 10 y 70 caracteres.
Descripción
Drug Development & Delivery is a print and online publisher that presents the latest scientific methods in drug development for professionals.
Longitud : 142
Genial, tu descripción meta contiene entre 70 y 160 caracteres.
Palabras Claves (Keywords)
Muy mal. No hemos encontrado palabras clave (meta keywords) en tu página. Usa este generador de meta tags gratuito para crear tus palabras clave.
Propiedades Meta Og
Bien. Tu página usa propiedades Og (etiquetas og).
| Propiedad | Contenido |
|---|---|
| locale | en_US |
| type | website |
| title | Drug Development & Delivery - The latest scientific methods in drug development |
| description | Drug Development & Delivery is a print and online content provider that presents the latest scientific methods in drug development for professionals in R&D, APIs, pre-formulation, formulation development and analytical methods. |
| url | https://drug-dev.com/ |
| site_name | Drug Development and Delivery |
| image | https://drug-dev.com/wp-content/uploads/2018/06/Drug-Dev-Homepage.jpg |
| image:width | 2048 |
| image:height | 1062 |
| image:type | image/jpeg |
Titulos
| H1 | H2 | H3 | H4 | H5 | H6 |
| 1 | 4 | 52 | 6 | 1 | 0 |
- [H1] Don’t miss out on this exclusive content!
- [H2] EXPERT CONTENT & RESOURCES
- [H2] EXCLUSIVE WHITEPAPERS
- [H2] EXCLUSIVE WEBINARS
- [H2] MARKET NEWS & TRENDS
- [H3] SPECIAL FEATURE - Artificial Intelligence in Drug Discovery, Development & Delivery
- [H3] FORMULATION FORUM - Solid Oral Dosages: Controlled Release of Drugs
- [H3] LEADERSHIP PANEL - Trends to Watch for in 2026
- [H3] PREFILLABLE SYRINGE SYSTEM - Beyond Components: Designing Prefillable Syringe Systems to Streamline Success
- [H3] CONTROLLED RELEASE - Challenges in Consistent & Predictable Delivery of Drugs Using Oral Controlled Release Technologies
- [H3] EXECUTIVE INTERVIEW - Incannex Healthcare: Pioneering the Future of Cannabinoid & Psychedelic Therapies
- [H3] CELL & GENE THERAPY - What the Industry Can Learn From Baby KJ About Optimizing CRISPR Development
- [H3] PLATFORM TECHNOLOGY - How PolyPid’s PLEX Unlocks the Potential of Local & Prolonged Release
- [H3] MAB FORMULATION & FILL-FINISH - Obstacles in Monoclonal Antibody Formulation & Fill-Finish
- [H3] EXECUTIVE INTERVIEW - CERo Therapeutics: A Novel Approach to Treating Cancer
- [H3] MRNA THERAPEUTICS - Strategies for Enhanced Stability, Targeted Delivery & Safe Translation
- [H3] 2026 COMPANY PROFILES & CAPABILITIES
- [H3] PURIFICATION STRATEGIES - Purification at Scale: Overcoming Chromatography Challenges for Advanced Modalities
- [H3] DRUG DEVELOPMENT - Common CMC Pitfalls in Orphan Drug Development
- [H3] 3D PRINTING - The Future of 3D Printing in Pharma: Aprecia’s Vision for Transformative Medicine
- [H3] Biocatalysis Without Barriers for Efficient Small Molecule Process Development
- [H3] VIDEO - Built for the Clinic: Smart Drug Product Design for Accelerated Clinical Development
- [H3] Atossa Therapeutics: Unlocking the Platform Potential of (Z)-Endoxifen Across Oncology & Rare Disease
- [H3] Drug Combination Screening in Oncology: Advancing Predictive Strategies for Precision Drug Development
- [H3] How Can a Stage-Based Program to Determine HME Applicability Benefit Your API?
- [H3] WHITE PAPER - Stop Guessing. Start Predicting: Rethinking Early Oral Drug Development
- [H3] WHITE PAPER - Small Molecules: Choosing the Right Development Path
- [H3] WHITE PAPER - How Advanced Containment Technology Is Reshaping High-Potency API Micronization
- [H3] WHITE PAPER - Advancements in Intradermal Delivery: From Historic Techniques to Modern Innovations
- [H3] WHITE PAPER - An Insoluble Problem? Overcoming Oral Drug Solubility Challenges With Functional Polymers
- [H3] ON-DEMAND WEBINAR: Drug Product Design for Delivery of Challenging Molecules
- [H3] WEBINAR - Vytal: The RTU Snap-Fit System for Container Closure Solutions – Setting the Standard for the Future
- [H3] WEBINAR ON DEMAND: Precision at Scale: Enabling Novel Therapeutics With Nanoparticle Manufacturing
- [H3] WEBINAR: Introducing Key Concepts in Tableting Research: Unleashing Essential Concepts and Strategies for Enhanced Formulation Development
- [H3] WEBINAR ON DEMAND: Advantages of Carbopol® Polymers in Oral Formulations
- [H3] Vetter Des Plaines Facility is the German American Chamber of Commerce’s Investment of the Year
- [H3] Neuland to Open Commercial Peptide Facility as part of Planned Phased Expansion
- [H3] Lonza & Genetix Biotherapeutics Extend Commercial Manufacturing Agreement for ZYNTEGLO
- [H3] Centauri Therapeutics Granted FDA QIDP Status for CTX-187 Treatment of Gram-Negative Bacterial Infections
- [H3] Upperton Submits MHRA License Application for Annex 1 Sterile Manufacturing Facility Following APS Validation
- [H3] Biologos Appoints New CEO, Celebrates 50 Years of Growth & Innovation
- [H3] Medicus Pharma Reports Positive Phase 2 Topline Data Observing 73% Clinical Clearance & 40% Histological Clearance
- [H3] LabVantage Solutions Introduces LabVantage CORTEX, Advancing its LIMS Platform for AI-Driven Laboratory Operations
- [H3] Codexis Signs Agreement to Manufacture 50 g siRNA Using its ECO Synthesis Manufacturing Platform
- [H3] FUJIFILM Biotechnologies Unveils ShunzymeX Precision Purification Technology
- [H3] BioDuro & Cenra Launch Joint Venture to Expand Resilient Global API Manufacturing Capacity
- [H3] NorthSea Therapeutics Announces Achievement of Key Regulatory Milestones for Orziloben
- [H3] ESTEVE CDMO Commences $15.5 Million Expansion of Chicago Small Molecule API Facility
- [H3] Bioxytran Reports Positive Study Results for a Broad-Range Antiviral Drug in Mild-to-Moderate COVID-19
- [H3] Quotient Sciences Extends Commercial Manufacturing Partnership for Ultra-Rare Disease Treatment
- [H3] Neurizon Initiates Dosing of NUZ-001 in HEALEY ALS Platform Trial
- [H3] MGS Acquires European-Based Medical Injection Molder Knudsen Plast A/S
- [H3] TARA-002 Demonstrates 68% Complete Response Rate at 6 Months in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
- [H3] etherna´s Intratumoral mRNA/LNP Platform Advances to Clinical Testing in Nonmelanoma Skin Cancer Led by Almirall
- [H3] SolasCure Completes Phase 2 Clinical Trial Demonstrating Accelerated Healing With Aurase Wound Gel
- [H3] MARKET SEGMENTS
- [H3] CORPORATE
- [H4] VIDEO SPOTLIGHT
- [H4] COMPANY PROFILES
- [H4] TECHNOLOGY & SERVICES SHOWCASE
- [H4] eBOOKS
- [H4] AUDIO SPOTLIGHT
- [H4] INDUSTRY EVENTS
- [H5] Sign Up for a free Subscription
Imagenes
Hemos encontrado 46 imágenes en esta web.
43 atributos alt están vacios o no existen. Agrega texto alternativo para que los motores de búsqueda puedan entender las imágenes.
Ratio Texto/HTML
Ratio : 31%
Ideal! El ratio entre texto y código HTML de esta página está entre 25 y 70 por ciento.
Flash
Perfecto, no se ha detectado contenido Flash en la página.
Iframe
Muy mal, tienes Iframes en la página, esto significa que el contenido no podrá ser indexado.
Enlaces SEO
Reescritura URL
Bien. Tus enlaces parecen amigables
Guiones bajos en las URLs
Perfecto! No hemos detectado guiones bajos en tus URLs
Enlaces en página
Hemos encontrado un total de 156 enlaces incluyendo 0 enlace(s) a ficheros
Palabras Clave SEO
Nube de Palabras Clave
announced delivery clinical formulation pharma drug solubility manufacturing development recently
Consistencia de las Palabras Clave
| Palabra Clave (Keyword) | Contenido | Título | Palabras Claves (Keywords) | Descripción | Titulos |
|---|---|---|---|---|---|
| drug | 38 |  |
 |
|
|
| development | 28 | |
|
|
|
| delivery | 20 | |
|
|
|
| pharma | 16 | |
|
|
|
| recently | 15 | |
|
|
|
Usabilidad
Url
Dominio : drug-dev.com
Longitud : 12
Favicon
Genial, tu web tiene un favicon.
Imprimibilidad
No hemos encontrado una hoja de estilos CSS para impresión.
Idioma
Genial. Has declarado el idioma en.
Dublin Core
Esta página no usa Dublin Core.
Documento
Tipo de documento (Doctype)
HTML 5
Codificación
Perfecto. Has declarado como codificación UTF-8.
Validez W3C
Errores : 0
Avisos : 0
Privacidad de los Emails
Genial. No hay ninguna dirección de email como texto plano!
HTML obsoleto
Genial, no hemos detectado ninguna etiqueta HTML obsoleta.
Consejos de Velocidad
|
Excelente, esta web no usa tablas. |
|
Muy mal, tu web está usando estilos embenidos (inline CSS). |
|
Muy mal, tu página web usa demasiados ficheros CSS (más de 4). |
|
Muy mal, tu sitio usa demasiados ficheros JavaScript (más de 6). |
|
Su sitio web se beneficia del tipo de compresión gzip. ¡Perfecto! |
Movil
Optimización Móvil
|
Icono para Apple |
|
Etiqueta Meta Viewport |
|
Contenido Flash |
Optimización
Mapa del sitio XML
¡Perfecto! Su sitio tiene un mapa del sitio en XML.
| https://drug-dev.com/sitemap_index.xml |
Robots.txt
https://drug-dev.com/robots.txt
¡Estupendo! Su sitio web tiene un archivo robots.txt.
Herramientas de Analítica
¡Perfecto! Su sitio web tiene una herramienta de análisis.
Google Analytics |
PageSpeed Insights
Dispositivo
Categorias
Free SEO Testing Tool
Free SEO Testing Tool es una herramienta seo gratuita que te ayuda a analizar tu web